Centessa Pharmaceuticals plc
CNTA
$39.76
$0.060.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.77% | -20.54% | -9.03% | -92.63% | 76.52% |
| Total Depreciation and Amortization | 166.57% | -251.48% | 4.87% | 4.15% | 158.65% |
| Total Amortization of Deferred Charges | -60.75% | 224.35% | -7.51% | -6.09% | -48.00% |
| Total Other Non-Cash Items | 41.64% | 17.46% | -17.79% | 31.28% | -84.24% |
| Change in Net Operating Assets | -573.03% | 110.83% | -161.05% | 148.00% | -252.67% |
| Cash from Operations | -29.42% | 4.30% | -159.72% | 60.78% | -33.75% |
| Capital Expenditure | -- | 95.30% | -85.71% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 119.58% | -450.80% | 256.12% | 82.09% | -989.55% |
| Cash from Investing | 119.58% | -452.14% | 255.04% | 82.03% | -989.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -87.97% | 7,861.29% | 108.91% | -78.34% | 48.19% |
| Repurchase of Common Stock | -1,976.14% | -40.80% | 97.22% | -2.28% | -176.62% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | 1,208.59% | -- |
| Cash from Financing | -89.25% | 8,145.56% | 114.14% | -47.99% | 4.15% |
| Foreign Exchange rate Adjustments | -89.19% | 435.93% | -343.36% | 92.55% | -150.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -89.84% | 69.61% | 110.78% | 78.09% | -2,255.48% |